Characterizing the immune effects of enfortumab vedotin and pembrolizumab (EV+P) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Bladder Cancer Advocacy Network
OpenAlex ID: W7162533764
Cites:
Cited by:
Related to: